Arthritis Drug Tocilizumab Found Effective in Treating Sickest COVID-19 Patients
By HospiMedica International staff writers Posted on 20 Nov 2020 |
Image: Anti-inflammatory drug tocilizumab (Actemra) (Photo courtesy of Roche)
Critically ill COVID-19 patients treated with the arthritis drug tocilizumab are significantly more likely to have improved outcomes, according to a new study.
The early findings, which are yet to be published, come from the REMAP-CAP trial, led by the Imperial College London (London, UK) and the Intensive Care National Audit & Research Centre (ICNARC) in the UK and Utrecht University (Utrecht, the Netherlands). The trial evaluates the effect of treatments on a combination of survival and length of time patients need support in an intensive care unit (ICU).
The results show that treatment with tocilizumab, an immunosuppressive drug used to treat rheumatoid arthritis, reached a key efficacy endpoint among critically ill patients with severe COVID-19, compared to patients who did not receive any immune modulation treatment. Patients receiving tocilizumab were more likely to improve (measured by a combination of organ support, such as a breathing machine, in the ICU and surviving the hospital admission) compared to patients who received no immune modulator.
The relative contribution of survival and reduced length of time needing organ support in ICU has not yet been analyzed. The trial does not yet know the relative benefits of tocilizumab compared to the other immune modulators. Further data are expected in the coming weeks and months. Due to the clinical implications for patients, the researchers have released the findings before they have been peer-reviewed, but are working to analyze and publish the full results as soon as possible.
“These early findings show that treatment with this immune modulating drug is effective for critically ill COVID-19 patients in intensive care units,” said Professor Anthony Gordon, Chair in Anesthesia and Critical Care at Imperial College London and a Consultant in Intensive Care Medicine at Imperial College Healthcare NHS Trust. “When we have the results available from all participants, we hope our findings will offer clear guidance to clinicians for improving the outcomes of the sickest COVID-19 patients.”
Related Links:
Imperial College London
Utrecht University
The early findings, which are yet to be published, come from the REMAP-CAP trial, led by the Imperial College London (London, UK) and the Intensive Care National Audit & Research Centre (ICNARC) in the UK and Utrecht University (Utrecht, the Netherlands). The trial evaluates the effect of treatments on a combination of survival and length of time patients need support in an intensive care unit (ICU).
The results show that treatment with tocilizumab, an immunosuppressive drug used to treat rheumatoid arthritis, reached a key efficacy endpoint among critically ill patients with severe COVID-19, compared to patients who did not receive any immune modulation treatment. Patients receiving tocilizumab were more likely to improve (measured by a combination of organ support, such as a breathing machine, in the ICU and surviving the hospital admission) compared to patients who received no immune modulator.
The relative contribution of survival and reduced length of time needing organ support in ICU has not yet been analyzed. The trial does not yet know the relative benefits of tocilizumab compared to the other immune modulators. Further data are expected in the coming weeks and months. Due to the clinical implications for patients, the researchers have released the findings before they have been peer-reviewed, but are working to analyze and publish the full results as soon as possible.
“These early findings show that treatment with this immune modulating drug is effective for critically ill COVID-19 patients in intensive care units,” said Professor Anthony Gordon, Chair in Anesthesia and Critical Care at Imperial College London and a Consultant in Intensive Care Medicine at Imperial College Healthcare NHS Trust. “When we have the results available from all participants, we hope our findings will offer clear guidance to clinicians for improving the outcomes of the sickest COVID-19 patients.”
Related Links:
Imperial College London
Utrecht University
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans